Durezol approved to relieve pain and inflammation after ophthalmic surgery


FDA has cleared a new steroid to treat patients after ocular surgery.

Durezol (difluprednate ophthalmic emulsion) 0.05%, a topical ophthalmic corticosteroid, has just received approval after priority review by the Food & Drug Administration. Sirion Therapeutics, the maker of the product, claims it’s the first ophthalmic steroid to be indicated for the treatment of both postoperative inflammation and pain associated with ocular surgery. The Tampa, Fla.,

Related Videos
fake news misinformation | Image Credit: Bits and Splits - stock.adobe.com
Dr. Charles Lee
© 2024 MJH Life Sciences

All rights reserved.